Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06752356 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT06752356 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 161 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06752356, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Conditions Studied
Interventions
- BIOLOGICAL Immune globulin (human) 10% solution for intravenous administration
Study Locations (1)
Texas
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06752356
The ClinicalTrials.gov registry entry for NCT06752356 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The listed sponsor is Kedrion S.p.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Immune globulin (human) 10% solution for intravenous administration is the first listed.
NCT06752356 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06752356 about?
NCT06752356 is a clinical study titled "A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
What is the current status of trial NCT06752356?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2026-04. Estimated completion is 2027-12-27.
What conditions does trial NCT06752356 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06752356?
The interventions under investigation include: Immune globulin (human) 10% solution for intravenous administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT06752356?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06752356 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.